Longitudinal imaging study of Alzheimer's disease
Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study
This study is testing how the buildup of certain proteins in the brains of people with different types of Alzheimer's disease changes over a year to better understand the disease's progression.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 21 Years to 80 Years |
| Sex | All |
| Sponsor | Mayo Clinic Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Rochester, Minnesota) |
| Trial ID | NCT02740634 on ClinicalTrials.gov |
What this trial studies
This study focuses on neuroimaging to investigate the amyloid and tau burden in the brains of patients with both typical and atypical forms of Alzheimer's Disease over a one-year period. Participants will undergo imaging with F-18 AV 1451 and C-11 PiB to assess changes in their condition. The study aims to enhance understanding of how these burdens evolve and their implications for disease progression. It includes patients diagnosed with conditions such as Logopenic Progressive Aphasia and Posterior Cortical Atrophy.
Who should consider this trial
Good fit: Ideal candidates are individuals over 21 with a diagnosis of typical amnestic Alzheimer's Disease or atypical syndromes like Logopenic Progressive Aphasia or Posterior Cortical Atrophy.
Not a fit: Patients with early episodic memory impairment or those diagnosed with other neurodegenerative disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and therapeutic strategies for Alzheimer's Disease.
How similar studies have performed: Other studies utilizing neuroimaging techniques to assess Alzheimer's Disease have shown promising results, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Over the age of 21 * Must have an informant who will be able to provide independent evaluation of functioning * English is primary language * All subjects must have insidious onset, report progression of their symptoms, and meet current clinical diagnostic criteria for typical amnestic AD or an atypical AD syndrome such as Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA). * All subjects with Logopenic Aphasia (LPA) must present with early and dominant impairments in language * All subjects with typical amnestic AD must have relative preservation of episodic memory compared to impairment in the non-episodic memory domain Exclusion Criteria: * If you have had a stroke or tumor that could explain your symptoms * Subjects that present with early episodic memory impairment or meet clinical criteria for mild cognitive impairment will not be recruited into the study * Subjects that meet specific criteria for another neurodegenerative disorder, including behavioral variant frontotemporal dementia, semantic dementia, primary progressive apraxia of speech, probable corticobasal syndrome, or progressive supranuclear palsy, will be excluded * Subjects will be excluded if they have poor vision (20/400) * Women that are pregnant or post-partum and breast-feeding will be excluded * Subjects will be excluded from the study if they are unable to undergo the tau-PET scan due to a prolonged QT interval on ECG, or if they have any of the following genetic conditions which can increase the chance of cancer: Cowden disease, Lynch syndrome, hypogammaglobulinemia, Wiskott-Aldrich syndrome, and Down's syndrome * Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, e.t.c.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma or intracranial neoplasm), or if they are medically unstable or are on medications that might affect brain structure or metabolism,(e.g. chemotherapy)
Where this trial is running
Rochester, Minnesota
- Mayo Clinic — Rochester, Minnesota, United States (Recruiting)
Study contacts
- Principal investigator: Jennifer Whitwell, Ph.D. — Mayo Clinic
- Study coordinator: Sarah M Boland, CCRP
- Email: boland.sarah@mayo.edu
- Phone: 507-284-3863
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.